Dublin, Sept. 07, 2017 -- The "Biomarkers - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering.
This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.
This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century.
Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.
Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.
Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.
Biomarker markets are estimated from 2016 to 2026 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.
A large number of companies with varying technical backgrounds are involved in biomarkers and 302 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 466 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies.
Key Topics Covered:
Part 1: Technologies & Applications
1. Introduction
2. Technologies for Discovery of Biomarkers
3. Biomarkers and Molecular Diagnostics
4. Biomarkers for Drug Discovery & Development
5. Role of Biomarkers in Healthcare
6. Biomarkers in Metabolic Disorders
7. Biomarkers in Immune Disorders
8. Biomarkers of Musculoskeletal Disorders
9. Biomarkers of Infectious Diseases
10. Biomarkers of Genetic Disorders
11. Biomarkers of Aging
12. Nutritional Biomarkers
13. Biomarkers of Cancer
14. Biomarkers of Disorders of the Nervous System
15. Biomarkers of Cardiovascular Disorders
16. Biomarkers of Pulmonary Diseases
17. Biomarkers in Gynecology and Obstetrics
18. Biomarkers & Personalized Medicine
19. Biomarkers and Regulatory issues
20. References
Part 2: Companies
21. Markets for Biomarkers
22. Companies
For more information about this report visit https://www.researchandmarkets.com/research/dtkh2v/biomarkers
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biomarkers


ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



